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Abstract
Chronic anemia-induced hypoxia triggers regulatory pathways that mediate long-term 
adaptive cardiac and cerebral changes, particularly at the transcriptional level. These 
adaptative mechanisms include a regulated cerebral blood flow and cardiac output, 
angiogenesis and cytoprotection triggered by hypoxia-inducible factor 1 alpha (HIF-1α), 
vascular endothelial growth factor (VEGF), neuronal nitric oxide synthase (nNOS) and 
Epo pathways. All these compensatory mechanisms aim to optimize oxygen delivery and 
to protect the brain and heart from hypoxic injury. We reviewed the effects of chronic 
hypobaric hypoxia as well as chronic anemia in the heart and brain, and we compared for 
the first time the effects of chronic hypobaric hypoxia combined with a severe lack of Epo 
(chronic anemia) in these vital organs. Functional cardiac adaptations such as cardiac 
hypertrophy, increased cardiac output as well as angiogenesis occurred along with the 
activation of HIF1α/VEGF and Epo/EpoR pathways under chronic anemia or hypoxia. 
Similarly, cerebrovascular adaptations take place through the same molecular mecha-
nisms under chronic hypoxia or anemia. However, when both arterial pressure and con-
tent of oxygen are decreased, the cerebral and cardiac adaptative mechanisms showed 
their limitations. In addition, cerebral and cardiac cell injuries may have occurred fol-
lowing the combined effect of chronic anemia and hypoxia. By emphasizing the anemia 
and hypoxia-induced cerebral and myocardial adaptations, this review highlighted the 
crucial role of Epo in its non-erythropoietic functions such as angiogenesis and neuro-
protection. Indeed, a better understanding of these protective mechanisms is of great 
clinical importance to the development of new therapeutic strategies for the management 
of ischemic heart and brain.
Keywords: chronic hypoxia, chronic anemia, angiogenesis, cardiac function, cerebral 
blood flow, oxygen homeostasis, neuroprotection, HIF-1-VEGF-Epo
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1. Introduction
Inadequate level of oxygen like in chronic hypoxia or anemia is especially detrimental for 
cerebral and heart tissues. Indeed, hypoxia plays an important role in the pathogenesis of 
cerebral and myocardial ischemia, and chronic heart and lung diseases [1]. That is why spe-
cific mechanisms at a systemic, cellular and molecular level take place to maintain the oxygen 
homeostasis. It is important to clearly distinguish the differences between hypoxia and ane-
mia. Hypoxia is a reduction of arterial pressure of oxygen (PaO
2
), while anemia is a reduction 
of arterial content of oxygen (CaO
2
) as it occurs during a decrease in hemoglobin concen-
tration. This review focus mainly on chronic hypobaric hypoxia that occurs at high altitude 
and chronic anemia is referred to our model of transgenic mice that presents a constitutive 
erythropoietin deficiency. Furthermore, emphasis is placed on effects of chronic hypoxia and 
anemia in the cerebral and cardiac tissues. The discussion is mostly based on animal studies 
unless otherwise indicated, even though similarities of adaptative mechanisms are shown by 
human studies [2, 3].
Chronic hypoxia promotes angiogenesis by modulating the transcriptional regulator hypoxia-
inducible factor 1 alpha (HIF-1α), which in turn triggers the upregulation of the erythro-
poietin [4], a major factor of acclimatization to hypoxia. HIF-1α is a master regulator of the 
hypoxic response and its proangiogenic activities include regulation of vascular endothelial 
growth factor (VEGF), but also Epo and its receptors (EpoR) [1, 5]. Erythropoietin primarily 
regulates red blood cell formation, and Epo serum levels are increased under hypoxic stress 
(e.g., anemia and altitude) [6]. However, several non-hematopoietic functions of Epo and its 
receptors have been exposed by experimental studies using genetically modified mice [7]. It 
is of great clinical importance that Epo has been shown to have protective functions in many 
different tissues. Indeed, these studies using recombinant human EPO (rHuEPO) suggested 
new therapeutic indications of Epo for the management of ischemic injuries of several tissues 
such as myocardium and brain [8–10].
Epo-induced angiogenesis may lead to an improvement in brain perfusion since Epo protects 
vascular bed integrity and stimulates angiogenesis [11–14] by acting indirectly on endothelial 
cells via activation of VEGF/VEGF receptor system, which is the most important regulator of 
endothelial growth and angiogenesis. Furthermore, Epo may have a positive effect on cere-
bral vasculature in addition to the cerebral blood flow (CBF) through alteration in nitric oxide 
(NO) production, which mainly derived from arginine and catalyzed by endothelial nitric 
oxide synthase (eNOS) [15]. Therefore, it seems that cellular protection and angiogenesis in 
heart and brain tissues are the dual role of erythropoietin and VEGF. These both cytokines 
are triggered by HIF-1α to maintain an adequate cellular oxygen supply and protect the brain 
and heart against hypoxic and or anemic injuries.
Our model of erythropoietin-SV40 T antigen (Epo-TAgh) transgenic mice has a targeted dis-
ruption in the 5′ untranslated region of the Epo gene that dramatically reduces its expression. 
The homozygous animals are thus severely and chronically anemic [16, 17]. Therefore, these 
transgenic anemic mice provided us an interesting model to study the adaptive mechanisms 
to chronic anemia and hypoxia, especially in vital organs, such as brain and heart. The present 
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review aims to give a brief synthesis of adaptations to chronic hypoxia in the brain and heart 
tissues, in absence of Epo. The first part will briefly describe the similarities of the signaling 
process of hypoxia-induced angiogenesis, as well as the other mechanisms that take place to 
protect the brain and heart against anemic and hypoxic injuries. The second part will focus 
on these adaptations in response to chronic anemia due to Epo deficiency (in comparison 
with adaptations induced by hypoxia). The third part will mainly describe the effect of both 
constraints (anemia and hypoxia) in cerebral and cardiac tissues.
2. Adaptations to chronic hypoxia in cerebral and cardiac tissues
2.1. Brain under chronic hypoxia
In the central nervous system, cerebrovascular and energy metabolism adaptations occur 
under hypoxic conditions in order to preserve an adequate tissue oxygen supply needed to 
support an optimal neuronal function. An acute hypoxic exposure triggers both a CBF and 
glucose consumption increases [18]. The stabilization of HIF-1α rapidly up regulates the vaso-
dilatory enzyme inducible nitric oxide synthase (iNOS) [19]. NO, the enzymatic product of 
iNOS, relaxes vascular smooth muscle cells, providing a short-term increase in blood flow. 
Thus, an increase in cerebral NO following a rise in NOS isoforms expression is most prob-
ably responsible for the rise in CBF [20–23]. With longer hypoxic exposure, polycythemia and 
cerebral angiogenesis take place to enhance cerebral oxygenation, while cerebral NO level 
returns to basal value [23, 24]. Indeed, in a chronic hypoxic challenge to the central nervous 
system, the cerebral cortex is known to undergo a significant cerebrovascular remodeling, 
in order to preserve tissue oxygen and energy supply [24–29]. These microvascular changes 
occur relatively late compared to the physiological adaptations [30]. In the rat brain, the capil-
lary density almost doubles, and the average intercapillary distance decreases from about 50 
to about 40 μm [31]. Also, by 3 weeks of adaptation, the initial hypoxic-induced increased flow 
returns to baseline by 5 days [22], concomitantly there is an increasing hematocrit, glucose 
consumption is slightly elevated by about 15% [32–34] and tissue oxygen tension is restored 
[35, 36]. Finally, it is well accepted that blood flow alterations serve acute changes in oxygen 
delivery, while persistent changes are due to capillary density adjustments.
Molecular mechanisms underlying hypoxia-induced capillary increases are now well docu-
mented and involve specifically HIF-1α/VEGF pathway [23, 26, 33, 37, 38]. The HIF pathway 
regulates a host of pro-angiogenic genes, including VEGF, angiopoietin-1, angiopoietin-2 (Ang-
2) and many others [39, 40]. HIF-regulated pro-angiogenic factors execute the HIF-specific 
angiogenic program by increasing vascular permeability (most probably through interaction 
with NO [41]), endothelial cell proliferation, sprouting, migration, adhesion and tube forma-
tion. In rats, HIF-1α is detected in the brain, in all cell types, shortly after the onset of hypoxia 
and persists for at least 2 weeks, until cerebral angiogenesis is completed within 3 weeks of 
exposure to hypoxia [23, 29, 35]. Brain angiogenesis also requires additional pro-angiogenic 
factors such as Ang-2. Ang-2, which is not constitutively expressed under normoxic conditions, 
is upregulated in rat and mouse endothelial cells following hypoxia [28, 38]. Ang-2 induction 
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during hypoxia is known to occur independently of HIF-1 and is due to cyclooxygenase-2 
(COX-2) enzyme activity [42, 43]. More recent results also demonstrated that the hypoxic capil-
lary response in aged mice was preserved after 3 weeks of hypoxia despite a significant delay 
in the response during the first week of exposure to hypoxia [25].
2.2. Heart under chronic hypoxia
In humans, the most characteristic and important cardiovascular response to hypoxia is pul-
monary vasoconstriction, which reduces the caliber of pulmonary vessels and raises vascular 
resistance in a region of low alveolar PO
2
. However, severe hypoxia has a direct deleterious 
effect on cardiac function. Hypoxic pulmonary vasoconstriction can cause chronic pulmonary 
hypertension. Myocardial contractility and maximum output are diminished during condi-
tions of reduced oxygen supply. While maximum oxygen consumption is reduced in chronic 
hypoxia, cardiac output (CO) remains normal at rest, owing primarily to an increased red 
blood cell mass [44, 45].
In our animal model, we showed that all parameters of cardiac function were preserved when 
comparing wild-type (WT) mice under normoxic and chronic hypoxic conditions. Indeed, 
systolic blood pressure was not affected by 14-day hypoxia at 4500 m, and hypoxic wild-type 
mice did not develop pulmonary hypertension. Moreover, there was no cardiac hypertro-
phy at variance with what was shown in rats or humans in similar hypoxic conditions [46]. 
Moreover, cardiac output was not affected by chronic hypoxia alone and oxygen delivery was 
maintained. In addition, hypoxic wild-type mice responded by increasing plasma Epo and 
blood hemoglobin, resulting in a rise in oxygen-carrying capacity [47].
Furthermore, many reports now stated that heart could be an additional Epo productive tis-
sue [48, 49]. Hoch et al. first showed an Epo gene and protein expression in cardiac pro-
genitor cells [50]. Through specific binding to its receptor EpoR, Epo triggers intracellular 
signaling events that depend on the activation of Jak2 tyrosine kinase [51]. The exploration of 
these pathways revealed that Epo is also an angiogenic as well as an anti-apoptotic factor as 
described respectively in the brain [52] and the heart [47, 50, 53, 54]. As previously described 
[55], chronic hypoxia led to the activation of HIF-1α/VEGF pathway in the heart of adult 
wild-type mice most probably responsible for their enhanced myocardial angiogenesis. Also 
we demonstrated the activation of cardioprotective pathways, involving HIF-1α and Epo, as 
suggested by the increase of EpoR expression and P-STAT-5/STAT-5 ratio [47]. Furthermore, 
we could not exclude a cardiac metabolic gene remodeling since temporal changes in glucose 
metabolic genes in response to moderate hypobaric hypoxia [56] have been demonstrated.
However, these adaptive responses contribute to maintain an adequate tissue oxygen supply 
for the preservation of cardiac function and to protect the heart against hypoxic insults.
3. Adaptations to chronic Epo deficiency in cerebral and cardiac tissues
Anemia is defined as a lack of oxygen-carrying red blood cells which also results in a lack of 
oxygen delivery to tissue. The physiological and molecular responses to tissue hypoxia are 
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increasingly understood while the effects of anemia are still poorly documented [57]. Our 
model of erythropoietin-SV40 T antigen (Epo-TAgh) transgenic mice presents a severe reduc-
tion of Epo expression that induces chronic anemia [16, 17]. The first studies demonstrated 
that Epo-Tagh mice could survive in chronic hypoxia (14 days at 4500 m), in part through an 
increase in ventilation and probably a higher cardiac output as suggested by a significant car-
diac hypertrophy [58–60]. Hence, it was of interest of our team to compare the physiological 
and cellular responses to chronic anemia (low Hb) and chronic hypoxia (low P
a
O
2
) in cerebral 
and cardiac tissues. Indeed, the objectives of our studies were to determine if chronic ane-
mic mice developed compensatory mechanisms in the brain and heart (vascular remodel-
ing, adaptative function, pathways involving HIF-1α) to offset the decrease in hemoglobin 
concentration.
3.1. Brain under chronic anemia
Low O
2 
environment is the principal regulator of HIF activity. The HIF pathway mediates the 
primary cellular responses to low O
2
, which promotes both short- and long-term adaptation 
to hypoxia as already described in the previous paragraph. In this regard, we considered 
that anemia-induced cerebral hypoxia involved the same hypoxic molecules. It has already 
been described that anemia increases cerebral hypoxic genes expression such as HIF, VEGF 
and nNOS which are involved in O
2
 homeostasis [61]. Indeed, studies on severe hemodilu-
tion using NOS-deficient mice showed an increased expression of HIF and nNOS proteins in 
the brain as well as an increased whole body HIF activity [57, 61–64]. Many other molecules, 
including Epo, VEGF and iNOS have also been shown to be upregulated in the anemic brain 
[61, 65]. Thus, it seems that during anemia, HIF-1α has the potential to regulate cerebral cel-
lular responses under both hypoxic and normoxic conditions [23, 47, 57, 64, 65].
Then, we focused on potential mediators of the increase in CBF associated with both hypoxia 
and anemia. Indeed, local production of NO by endothelial NOS (eNOS), and nNOS mediates 
CBF under a number of physiological conditions, including anemia and hypoxia [24, 61, 63, 
64]. Relatively specific inhibition of nNOS has been demonstrated to impair the increase in 
CBF associated with acute anemia [61] and hypoxia [66–68], implicating nNOS as an impor-
tant mediator of CBF in both cases [63, 64]. In our studies, we also found an increase in nNOS, 
while iNOS and eNOS were unchanged but no corresponding change in cerebral NO con-
centration. The stabilization of HIF-1α, as already described in the brain in acute [61, 69] and 
chronic anemia [23], promote VEGF-induced angiogenesis as shown in normoxic Epo-TAgh 
mice with a rise in the capillary/fiber ratio, thus optimizing oxygen diffusion as previously 
described in the brain [24]. Erythropoietin also plays an important role in angiogenesis through 
upregulation of VEGF in ischemic rats [11]. Indeed, Wang et al. showed that neural progenitor 
cells treated with Epo were able to produce VEGF and consequently to promote angiogenesis 
through the upregulation of VEGFR2 expression in cerebral endothelial cells [70].
Our work provided novel physiological data about cerebral adaptations to chronic anemia. 
Indeed, we evidenced that Epo deficiency activated cerebral hypoxic mechanisms through 
HIF activation that promote angiogenesis [23]. In addition, the JAK/STAT signaling pathway 
mediated by the Epo/EpoR complex seems to be activated by chronic anemia [23, 47] and 
Adaptations to Chronic Hypoxia Combined with Erythropoietin Deficiency in Cerebral and Cardiac Tissues
http://dx.doi.org/10.5772/66974
165
could promote neuroprotection and cell proliferation [71]. Furthermore, more recent results 
showed that nNOS is specifically protective during anemia [57]. All these responses were 
probably able to minimize brain damage that could be induced by chronic anemia. Finally, 
the mechanisms responsible for matching capillary density to tissue oxygen levels are not 
unique to environmental hypoxic stimuli. Rather, these processes appear to be responsible 
for maintaining the oxygen availability through local blood flow in order to optimize the 
neuronal function.
3.2. Heart under chronic anemia
The classic physiological cardiovascular responses to anemia include an increased CO, a redis-
tribution of blood flow and a decrease of hemoglobin-oxygen affinity. Two mechanisms are 
most probably responsible for the increased CO during anemia: reduced blood viscosity and 
increased sympathetic stimulation of the cardiovascular effectors. Blood viscosity affects both 
preload and afterload, two of the major determinants of the CO, whereas sympathetic stimu-
lation primarily increases heart rate and contractility [72]. If cardiac function is normal, the 
increase in venous return or left ventricular preload will be the most important determinant of 
the increased CO during normovolemic anemia [72]. It is also known that anemia induces right 
and left ventricular hypertrophy [59, 73, 74] and increases CO, offsetting the fall in arterial oxy-
gen content to maintain oxygen delivery. Our data confirmed the increase in CO by an increase 
in the stroke volume associated with a left ventricular dilatation as expected by Olivetti et al. 
[74]. Taken together, these data suggest that the enhancement in CO could be explained by 
both an increase in preload and autonomous nervous system stimulation. Indeed, our data 
showed an increase in myocardial function parameters in normoxic anemic mice. However, 
although the CO was increased in Epo-Tagh mice, oxygen delivery remained lower than in con-
trols. This could induce the stabilization of the transcription factor HIF-1α as already described 
in the brain in both models of acute and chronic anemia [61, 69]. This stabilization promotes 
VEGF-induced angiogenesis as shown in normoxic Epo-TAgh mice with a rise in the capillar-
ies/fibers ratio, thus optimizing oxygen diffusion as described in the brain [24]. This increase 
in capillary density could allow the development of cardiac hypertrophy without myocardial 
dysfunction, as previously described in rats in a model of anemia induced by iron-deficient 
diet [74]. Furthermore, we could not exclude that increased expression of nNOS also contrib-
uted to these adaptive cardiovascular responses in chronic anemic mice. Indeed, acute anemia 
resulted in an increase in CO and a reduced stroke volume in WT anemic mice while in con-
trast, CO and stroke volume responses were severely attenuated in anemic nNOS−/− mice [57]. 
In addition, a model of Hif1a+/− hemizigous mice revealed impaired increases in hematocrit, 
right ventricular mass and right ventricular pressure, allowing us to speculate that increased 
HIF-1α may have participated in these physiological responses to anemia in our model [75].
4. Effects of chronic anemia and hypoxia on cerebral and cardiac tissues
As previously explained, plethora of studies are available to describe cerebral and cardiac 
adaptations and their underlying molecular mechanisms in response to chronic hypoxia or 
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anemia separately. Our group investigated for the first time, the effects of chronic hypobaric 
hypoxia combined with chronic anemia in the heart and brain of the transgenic Epo-TAgh 
mice. So far, the few studies from other groups that also use transgenic mice overexpressing 
Epo (Tg6 and Tg21) display results that are complementary to our data but also more detailed. 
Indeed, these studies also describe the pathways involved in the ventilatory responses to 
hypoxia and aim to clarify the role of Epo in respiratory acclimatization to hypoxia at physi-
ological, cellular and molecular levels. Even though, we were not able to find other animal 
studies combining the effects of both chronic hypoxia and anemia on cardiac or cerebral tis-
sues, comparing studies at a multidisciplinary level may provide new approaches and thera-
pies for diseases associated with hypoxia.
4.1. Brain under chronic hypoxia and anemia
In the brain, both Epo and its receptor are upregulated during ischaemia/hypoxia [76, 77] 
and Epo administration considerably inhibits apoptosis after middle cerebral artery occlu-
sion [78]. Apart from its positive effects in acute ischaemic brain damage, Epo is a potent 
stimulator of the hypoxic ventilatory response (HVR) by interacting with respiratory centers 
in the brainstem [79]. Indeed, the blockade of Epo’s activity in the brainstem of adult C57Bl6 
mice by intracisternal injections of the soluble Epo receptor (sEpoR) induced a reduction of 
the basal minute ventilation, but it did not affect the central chemosensitivity [80, 81]. In con-
trast, recent study using transgenic mice Tg6 (that present a human Epo gene overexpression 
in brain and circulation; Tg21: Epo overexpression in brain) suggested that Epo blunts the 
HVR through an interaction with central and peripheral respiratory chemocenters [81]. In our 
model, acute hypoxic ventilatory response was increased after chronic hypoxia in wild-type 
mice but remained unchanged in Epo-TAgh mice, confirming that adequate erythropoietin 
level is necessary to obtain an appropriate HVR and a significant ventilatory acclimatization 
to hypoxia. Surprisingly, both constraints (chronic hypoxia and anemia) did not trigger a syn-
ergic effect in any studied parameters except a high cerebral NO level that could suggest an 
improved brain perfusion. Finally, the response to chronic hypoxia was divergent in the brain 
of wild-type and anemic mice. Indeed, these adaptation processes including angiogenesis and 
neuroprotection were globally altered in Epo-TAgh mice exposed to chronic hypoxia.
Taken together, all these data suggest that Epo/EpoR pathways activation is necessary to ini-
tiate neuroprotection mechanisms as well as cerebral angiogenesis under hypoxia but also 
might help to better understand respiratory disorders at high altitude.
4.2. Heart under chronic hypoxia and anemia
Independently, chronic anemia and chronic hypoxia increased the expression of HIF-1α, 
VEGF and Epo, cytokines that are involved in both angiogenesis and cardioprotection through 
specific signaling pathways acting to compensate oxygen transport deficiency. Recent studies 
also involved these same cytokines in the cardiovascular responses as well as increased car-
diac output observed in acute anemia [57, 75]. Our data showed a decrease in left ventricular 
hypertrophy and functional left ventricular adaptation as well as a reduced oxygen delivery 
in the heart of hypoxic Epo-TAgh mice. Results from other groups showed that Tg6 mice did 
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not develop pulmonary hypertension in normoxia or after exposure to chronic hypoxia (10% 
O
2
 for 3 weeks) [82] suggesting an important role of Epo in functional adaptation of the heart 
to chronic hypoxia. Similarly to what occurred in the brain, we did not observe a synergic 
effect of these combined constraints on the expression of the hypoxic genes in the heart of 
chronically hypoxic Epo-TAgh mice suggesting that adaptive responses to both constraints 
are already maximal. However, the increased P-STAT-5/STAT-5 ratio is concordant with a 
direct protective effect of Epo on cardiomyocytes and endothelial cells as well as stimulation 
of angiogenesis in the ischaemic heart [83]. Capillary density was unchanged in spite of the 
fall in HIF-1α/VEGF pathway probably because the initiation of the capillarization with acute 
hypoxia necessitates VEGF, while its maintenance in chronic hypoxia involves other factors 
such as angiopoietins [38, 43].
Taken together, our results suggest that adaptative mechanisms that take place with chronic 
anemia are somewhat similar to those in response to 14 days of hypoxia. However, when both 
constraints are applied, these mechanisms failed to maintain an adequate cardiac adaptation 
with a secondary decrease in body oxygen supply, despite the activation of cardioprotective 
pathways.
5. Perspectives and significance
In this review, a proposal is made that chronic anemia-induced hypoxia triggers regulatory 
pathways that mediate long-term adaptive cardiac and cerebral changes, particularly at the 
transcriptional level. These adaptative mechanisms include a regulated increase in cerebral 
blood flow, cardiac output, angiogenesis and cytoprotection triggered by HIF-1α, VEGF and 
Epo pathways. All these compensatory mechanisms aim to optimize oxygen delivery and 
to protect the brain and heart from hypoxic injury to allow acclimatization. However, when 
both arterial pressure and content of oxygen are decreased, the cerebral and cardiac adapta-
tive mechanisms showed their limitations. We could not exclude that cerebral and cardiac cell 
injuries occurred following the combined effect of chronic anemia and hypoxia as well as of 
the NO toxicity. Figure 1 summarizes the cerebral and cardiac plasticity induced by chronic 
anemia and/or hypoxia. Data shown in this figure are all based on animal studies. Moreover, 
a recent review of our group includes also ventilatory [60], muscular [84, 85] and rheologic 
[86] adaptations in this model of mice. Finally, investigating the molecular mechanisms of 
O
2
 homeostasis represents a mean of gaining new insights to the hypoxia-induced cerebral 
and myocardial injuries. But it is of great clinical importance to study extensively these non-
erythropoietic functions of Epo to contribute to the development of new therapeutic strategies 
for the management of brain and heart ischemia.
Figure 1 summarizes the physiological adaptations to chronic hypoxia and anemia in the 
heart and brain of our model of Epo-TAgh mice. The green color represents the responses 
of normoxic anemic mice. The blue color represents the responses of hypoxic control mice. 
The red color represents the responses of hypoxic anemic mice. The arrows represent an 
increase or decrease of the response, while the ‘=’ symbol means no change between normoxia 
and hypoxia. PaO
2
 is arterial pressure of oxygen, CaO
2
 is arterial content of oxygen, PiO
2
 is 
inspired pressure of oxygen and TO
2
 is transport of oxygen.
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